Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Food Effect of Different Oral Formulations of AZD5004 in Healthy Participants
NCT07455825Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elecoglipron (4 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 extrapolated to infinity, Area under concentration-curve from time 0 to the time of last quantifiable concentration and 1 more. Started Mar 2026; status: completed.
02
Drugs
elecoglipron
Beyond the preview
Go deeper on NCT07455825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455825.